bioAffinity Technologies BBIAF announced a nationwide federal healthcare distribution agreement with AvMEDICAL for its CyPath Lung diagnostic test on August 18, 2026, opening a direct channel to Veterans Affairs and military health systems across the United States. Despite the strategic win, shares of the micro-cap biotech fell roughly 40% intraday, trading near $0.48 with a market capitalization of $2.18 million. Read more on the Market News hub.
What happened
bioAffinity Technologies and AvMEDICAL entered a distribution agreement covering federal healthcare facilities, including VA hospitals, military treatment centers, and other government-run clinics. The deal grants AvMEDICAL rights to distribute CyPath Lung, bioAffinity's non-invasive lung cancer diagnostic test, nationwide under the federal health channel. The announcement was made before market open on August 18, 2026, at 8:06 AM Eastern.
CyPath Lung uses flow cytometry to analyze patient samples and assess lung cancer risk, targeting the pulmonary nodule population identified through low-dose CT screening. The test is designed to address a growing clinical need for better risk stratification in early lung cancer detection.
BIAF reported Q2 2026 earnings on August 7, 2026, beating consensus estimates with an EPS of -0.64 versus the -2.10 estimate. Revenue for the quarter came in at $1.51 million against a $1.70 million estimate. Management highlighted continued commercial momentum, with quarterly CyPath Lung sales doubling to a new record in Q2. The company employs 57 people and is headquartered in San Antonio, Texas.
Shares outstanding total approximately 4.5 million, with a float of 4.4 million and short interest covering just 1.5 days of average volume.
Why it matters
The federal distribution agreement represents a meaningful expansion of CyPath Lung's addressable market. VA and military health systems serve a large, high-risk population for lung cancer, including veterans with significant smoking histories and occupational exposures. Reaching these channels through an established federal distributor reduces the sales and logistics burden on a company of BIAF's small scale.
For investors, the deal underscores ongoing commercial execution despite a severely compressed stock price. The EPS beat in Q2, combined with record quarterly sales and now a federal distribution win, suggests the CyPath Lung rollout is gaining traction. However, the stock's sharp decline on the news day signals that the market is pricing in significant dilution risk, capital constraints, or broader sentiment headwinds for micro-cap biotechs. With a market cap under $2.5 million, BIAF remains a speculative, low-volume name.
What to watch next
BIAF is scheduled to report its next earnings cycle on August 19, 2026. Investors should monitor whether the distribution deal accelerates near-term revenue expectations or if the company provides updated guidance tied to federal channel ramp-up. Follow-on catalysts include VA site onboarding timelines, initial order volumes from AvMEDICAL, and any announcements around reimbursement progress with federal payers.